Abacavir and lamivudine combination

Expert Opinion on Drug Metabolism & Toxicology
Charurut SomboonwitAna Paula Velez

Abstract

Fixed dose antiretroviral combinations (FDC) may improve therapy adherence with reduced pill burden. Abacavir and lamivudine are well-established nucleoside reverse-transcriptase inhibitors available as a once-daily FDC. Abacavir is currently considered an alternative treatment option in most established treatment guidelines based on associations with cardiovascular events and lesser efficacy in patients with higher baseline viremia. To summarize rigorous clinical trial data and cohort studies that examine efficacy, safety and tolerability of the individual components and the FDC of abacavir-lamivudine. Clinical trial data, post-marketing research findings and clinical cohort data were reviewed to assess the efficacy, safety and tolerability of the individual components and the FDC of abacavir-lamivudine along with recommendations from published clinical treatment guidelines. The efficacy of abacavir-lamivudine is well documented in numerous clinical studies and treatment guidelines. The introduction of laboratory testing to identify patients at risk for hypersensitivity has decreased the incidence of these reactions. Recent findings suggest that abacavir is an alternative treatment agent with baseline HIV RNA > 100,000 copies/...Continue Reading

References

Dec 5, 2002·Clinical Therapeutics·Patrick G Clay
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Edwin DeJesusUNKNOWN CNA30024 Study Team
Mar 15, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Graeme J MoyleUNKNOWN Ziagen Once-Daily in Antiretroviral Combination Therapy (CNA30021) Study Team
Dec 1, 2006·The New England Journal of Medicine·UNKNOWN Strategies for Management of Antiretroviral Therapy (SMART) Study GroupC Rappoport
Feb 8, 2008·The New England Journal of Medicine·Simon MallalUNKNOWN PREDICT-1 Study Team
Aug 5, 2008·JAMA : the Journal of the American Medical Association·Scott M HammerUNKNOWN International AIDS Society-USA
Mar 14, 2009·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Cindy H BrothersDidier H Lapierre

❮ Previous
Next ❯

Citations

Sep 5, 2012·Expert Opinion on Drug Metabolism & Toxicology·Alessia UgliettiRenato Maserati

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.